Sanofi/Regeneron
Pays vs peer median
×0.97
-3% premium
Sample
3
low confidence
Last refreshed
2026-07-01
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Pipeline coverage & gaps
Sanofi/Regeneron has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Oncology
Gap
No disclosed deals
Neurology
Gap
No disclosed deals
Immunology
Gap
No disclosed deals
Metabolic
Gap
No disclosed deals
Cardiovascular
Gap
No disclosed deals
Infectious Disease
Gap
No disclosed deals
Ophthalmology
Gap
No disclosed deals
Womens Health
Gap
No disclosed deals
Rare Disease
Gap
No disclosed deals
Hematology
Gap
No disclosed deals
Dermatology
Gap
No disclosed deals
Gastroenterology
Gap
No disclosed deals
Recent disclosed deals
No deal records found for this buyer.
How this is computed
For each Sanofi/Regeneron deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.971, clamped to [0.7, 1.5].